Add to ORKGThe Author(s) 2015. This article is published with open access at Springerlink.com Introduction: Studies have shown that, at low doses and with careful titration, combination therapy with intrathecal ziconotide and morphine results in rapid control of opioid-refractory cancer pain. However, ther
This article summarizes recommendations made by six pain specialists who discussed the rationale for...
Objectives: The aim of this open-label, non-randomized, clinical trial was to evaluate the feasibili...
The Author reports the case of a patient with severe lumbar pain unresponsive to NSAIDs. Initial tre...
Ziconotide is a nonopioid intrathecal analgesic drug used to manage moderate to severe chronic pain....
Introduction: In cancer-related pain refractory to systemic opioids, intrathecal (IT) administra- ti...
& Abstract: Chronic pain may recur after initial response to strong opioids in both patients wit...
The Author reports the case of ziconotide intrathecal treatment in three terminal cancer patients, ...
Cancer patients with complex and severe pain were treated with intrathecal continuous infusion of zi...
The authors describe the clinical case of a patient suffering from severe cervico-facial pain syndr...
This prospective trial investigates the effects of intrathecal Ziconotide combined with Morphine and...
Between 10% and 20% of cancer pain patients fail to obtain adequate pain relief despite comprehensiv...
Chronic pain related to PCOA is a clinical condition which affects more than 5 percent of the popula...
TheWHO ladder has been the most widely used approach for management of Cancer Pain. However, oral me...
This study presents the clinical case of a patient with paraparesis, subjected for a long period of ...
Abstract Patients who have refractory cancer pain suffer both physically and psychologically. Cancer...
This article summarizes recommendations made by six pain specialists who discussed the rationale for...
Objectives: The aim of this open-label, non-randomized, clinical trial was to evaluate the feasibili...
The Author reports the case of a patient with severe lumbar pain unresponsive to NSAIDs. Initial tre...
Ziconotide is a nonopioid intrathecal analgesic drug used to manage moderate to severe chronic pain....
Introduction: In cancer-related pain refractory to systemic opioids, intrathecal (IT) administra- ti...
& Abstract: Chronic pain may recur after initial response to strong opioids in both patients wit...
The Author reports the case of ziconotide intrathecal treatment in three terminal cancer patients, ...
Cancer patients with complex and severe pain were treated with intrathecal continuous infusion of zi...
The authors describe the clinical case of a patient suffering from severe cervico-facial pain syndr...
This prospective trial investigates the effects of intrathecal Ziconotide combined with Morphine and...
Between 10% and 20% of cancer pain patients fail to obtain adequate pain relief despite comprehensiv...
Chronic pain related to PCOA is a clinical condition which affects more than 5 percent of the popula...
TheWHO ladder has been the most widely used approach for management of Cancer Pain. However, oral me...
This study presents the clinical case of a patient with paraparesis, subjected for a long period of ...
Abstract Patients who have refractory cancer pain suffer both physically and psychologically. Cancer...
This article summarizes recommendations made by six pain specialists who discussed the rationale for...
Objectives: The aim of this open-label, non-randomized, clinical trial was to evaluate the feasibili...
The Author reports the case of a patient with severe lumbar pain unresponsive to NSAIDs. Initial tre...